CN100569230C - 含有双氯芬酸钠和β-环糊精的可注射药物组合物 - Google Patents
含有双氯芬酸钠和β-环糊精的可注射药物组合物 Download PDFInfo
- Publication number
- CN100569230C CN100569230C CNB2005100768303A CN200510076830A CN100569230C CN 100569230 C CN100569230 C CN 100569230C CN B2005100768303 A CNB2005100768303 A CN B2005100768303A CN 200510076830 A CN200510076830 A CN 200510076830A CN 100569230 C CN100569230 C CN 100569230C
- Authority
- CN
- China
- Prior art keywords
- solution
- diclofenac sodium
- diclofenac
- beta
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
本发明公开了一类可注射药物组合物,含有双氯芬酸钠、β-环糊精和聚山梨醇酯,它们适合用于皮下和肌肉给药。
Description
发明领域
本发明涉及药物组合物领域,特别涉及一种基于双氯芬酸钠的新型可注射药物组合物。
技术现状
双氯芬酸钠,即2-[(2,6-二氯苯基)氨基]苯乙酸单钠盐,具有公认的抗炎活性,并因此很久以来在用于治疗包括外伤引起的和手术后引起的疼痛症状和所有风湿类疾病的各种类型药物制剂中被用作有效成分。
双氯芬酸通过抑制前列素合成而起作用,这是引起炎症和疼痛的主要原因。为了获得最大的疼痛减轻效果,有效成分必须要尽可能地在用药后到达体循环,所以,可注射形式对于治疗肌肉-骨骼系统的急性炎症是特别受欢迎的。
假定双氯芬酸钠是一种微溶于水的化合物,则目前可获得的基于这种有效成分的可注射药物制剂,将含有等于75mg溶解在3ml溶剂中的数量,溶剂由30vol%丙二醇和70vol%水组成。
尽管如此,但是,这种制剂对于病人来说不是令人愉快的,这是因为它令人感觉疼痛;而且,对于给定的单一剂量的总体积来说,用药只有通过肌肉或静脉注射才是可能的。
为了克服因双氯芬酸在水中的低溶解度引起的这些问题,制备了一类组合物,在这类组合物中,双氯芬酸或其盐与环糊精结合。从这类主题的文献已经知道,由于环糊精能与这种有效成分形成一种水溶复合物,所以它们能提高双氯芬酸的溶解性,
但是,还知道即使在羟丙基-β-环糊精帮助下,如果双氯芬酸钠的浓度需要提高,例如,从25mg/ml提高到75mg/ml,则适合于注射的药物组合物,无论如何也不能得到,这是因为会形成双氯芬酸钠的晶体,如欧洲专利第658347B1号中所述。
所以,确定一种具有双氯芬酸钠浓度大于25mg/ml但不存在前述已知药物组合物缺点的可注射制剂的问题,还没有得到解决。
发明概述
本申请人已发现,通过添加非常精确浓度极限的聚山梨醇酯到一种含β-环糊精和浓度大于25mg/ml水的双氯芬酸钠的水溶液中,晶体形成就可得到完全抑制,从而获得在室温和4℃下能够长期保持清澈和稳定的溶液。
因此,本发明目的是一种呈水溶液形式的可注射药物组合物,包括浓度大于25mg/ml水的双氯芬酸钠和β-环糊精,其特征在于它含有至少一种聚山梨醇酯,其数量为所述溶液总体积的0.01~0.06wt%。
本发明药物组合物的特征和优点将在下文中作更详细的描述。
附图简要说明
图1:给出了双氯芬酸钠的血浆浓度相对于时间(在对三个健康志愿者使用实施例1组合物进行肌肉用药(-◆-)和皮下用药(--Δ--)后960分钟)的两个曲线。
发明详细说明
在本发明药物组合物中,优选使用的聚山梨醇酯是聚山梨醇酯20、或聚氧乙烯山梨糖醇单月桂酸酯,可在市场上以商品名20购得。本发明所述组合物中的聚山梨醇酯数量,相对于所述溶液总体积,为0.01~0.06wt%。
本申请人已经发现,如果同样聚山梨醇酯在前述范围之外的浓度进行使用,则无论是在室温还是在4℃,都不能获得令人满意的组合物稳定性结果。
如下文对比例2所述,聚山梨醇酯溶液浓度低于0.01%w/v,则会形成低温时双氯芬酸溶解性不能令人满意的组合物;事实上,在4℃经过一个相对简短贮存后,溶液中就会形成双氯芬酸晶体。从下文给出的对比例3,可以清楚地看出,如果在室温进行贮存,则聚山梨醇酯溶液浓度大于0.06%w/v,会给出相似的溶液稳定性不能令人满意的结果。
根据本发明药物组合物的特别优选实施方式,聚山梨醇酯数量,相对于溶液总体积,等于0.05wt%。
根据本发明优选实施方式,双氯芬酸钠与β-环糊精的摩尔比是在1∶1~1∶1.3范围之间。
β-环糊精优选为羟丙基β-环糊精。
除了有效成分环糊精和聚山梨醇酯之外,本发明药物组合物还可含有药物学可接受的赋形剂,它们选自于那些常用于药物组合物之中用以获得可注射溶液的赋形剂,可注射溶液对于通过肌肉方式或通过皮下方式是可注射的,并可用于治疗疼痛症状。
本发明组合物可以多种配制方法制备得到,特别地按照优选剂量单位75mg双氯芬酸钠制得。
本发明的药物组合物,可通过混合一种聚山梨醇酯水溶液与一种环糊精水溶液和接着添加双氯芬酸钠而制备得到。
已经发现,以前述水溶液形式制得的药物组合物,是长期稳定的,并且在制备后至少三个月没有晶体形成,无论是在室温还是在4℃。
下述的本发明非限制性实施例,是为说明目的而给出的。
实施例1
制备下述两种溶液:
-溶液B:在搅拌作用下将6.6g羟丙基β-环糊精溶解在约10ml脱离子水中,直到获得透明无色溶液。
在搅拌作用下,将1.50g的双氯芬酸钠和0.2ml前述制备的溶液A,添加到溶液B中。接着采用脱离子水,使该溶液达到20ml的最终体积,并使之处于搅拌作用之下达约40分钟。
在过滤通过0.22μm过滤器后,得到透明无色溶液,发现其双氯芬酸钠溶液浓度(采用UV分析)为72.91mg/ml。
此溶液按照可注射药物制剂采用的常用方法进行包装和贮存,于室温和4℃条件下,在多于三个月的时间仍保持清澈,没有晶体形成。
实施例2(对比例)
制备下述两种溶液:
-溶液B:在搅拌作用下将6.6g羟丙基β-环糊精溶解在约10ml脱离子水中,直到获得透明无色溶液。
在搅拌作用下,将1.51g的双氯芬酸钠和0.2ml前述制备的溶液A,添加到溶液B中。接着采用脱离子水,使该溶液达到20ml的最终体积,并使之处于搅拌作用之下达约40分钟。接着,溶液过滤通过0.22μm过滤器,得到透明无色溶液,发现其双氯芬酸钠溶液浓度(采用UV分析)为79.14mg/ml。
此溶液按照可注射药物制剂采用的常用方法进行包装和贮存,于室温条件下,在多于三个月的时间仍保持清澈,没有晶体形成,但在4℃条件下,在仅1个月之后,就观察到有呈酸形式和钠盐形式的双氯芬酸晶体形成。
实施例3(对比例)
在搅拌作用下将17.4g羟丙基β-环糊精溶解在约28ml脱离子水中,直到获得透明无色溶液。在搅拌作用下,将3.75g的双氯芬酸钠和90.1mg的20,添加到其中。
接着采用脱离子水,使该溶液达到50ml的最终体积,并使之处于搅拌作用之下达约40分钟。接着,溶液过滤通过0.22μm过滤器,得到透明无色溶液,发现其双氯芬酸钠溶液浓度(采用UV分析)为80.49mg/ml。
此溶液按照可注射药物制剂采用的常用方法进行包装和贮存。贮存在4℃下的溶液保持清澈,但贮存在室温条件下的相同溶液仅在贮存一周后就观察到混浊。
实施例4
人体的皮下药物动力学
将实施例1所述制备得到的且含有72.91mg/ml的双氯芬酸钠的溶液,于每个含75mg的双氯芬酸钠的小瓶中,在无菌状态下通过消毒过滤法进行消毒。
将该剂量消毒液(75mg)皮下注射到三个健康志愿者的大腿上部,在给药前,从这三个志愿者提取血液样品,在给药后,以一定时间间隔提取血液样品,直到960分钟。
在图1中,给出了血浆双氯芬酸钠水平随时间的变化曲线,由虚线与对应于检测的单个数值的三角形表示。
实施例5
人体的肌肉药物动力学
将实施例1所述制备得到的且含有72.91mg/ml的双氯芬酸钠的溶液,于每个含75mg的双氯芬酸钠的小瓶中,在无菌状态下通过消毒过滤法进行消毒。
将该剂量消毒液(75mg)肌肉注射到三个健康志愿者的大腿上部,在给药前,从这三个志愿者提取血液样品,在给药后,以一定时间间隔提取血液样品,直到960分钟。
在图1中,给出了血浆双氯芬酸水平随时间的变化曲线,由实线与对应于检测的单个数值的菱形表示。
Claims (5)
1、一种呈水溶液形式的注射用药物组合物,含有羟丙基-β-环糊精和浓度大于25mg/ml的双氯芬酸钠;其中,所述组合物还含有聚山梨醇酯20,其数量相对于所述溶液总体积,是在0.01~0.06wt%之间。
2、权利要求1所述药物组合物,其中,所述聚山梨醇酯20存在的数量,相对于所述溶液总体积,为0.05wt%。
3、权利要求1所述药物组合物,其中,双氯芬酸钠与羟丙基-β-环糊精的摩尔比是在1∶1~1∶1.3范围之间。
4、权利要求1所述药物组合物,其中,所述溶液中双氯芬酸钠浓度是75mg/ml。
5、权利要求1所述药物组合物,呈单位剂量含75mg的双氯芬酸钠的形式。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001245A ITMI20041245A1 (it) | 2004-06-22 | 2004-06-22 | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
ITMI2004A001245 | 2004-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1711996A CN1711996A (zh) | 2005-12-28 |
CN100569230C true CN100569230C (zh) | 2009-12-16 |
Family
ID=35033310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100768303A Active CN100569230C (zh) | 2004-06-22 | 2005-06-17 | 含有双氯芬酸钠和β-环糊精的可注射药物组合物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7423028B2 (zh) |
EP (1) | EP1609481B1 (zh) |
JP (1) | JP5113323B2 (zh) |
KR (1) | KR101202649B1 (zh) |
CN (1) | CN100569230C (zh) |
AT (1) | ATE373489T1 (zh) |
CA (1) | CA2510813C (zh) |
DE (1) | DE602005002495T2 (zh) |
DK (1) | DK1609481T3 (zh) |
ES (1) | ES2293482T3 (zh) |
IT (1) | ITMI20041245A1 (zh) |
PL (1) | PL1609481T3 (zh) |
PT (1) | PT1609481E (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095363A2 (en) | 2005-02-01 | 2006-09-14 | Troikaa Pharmaceuticals Ltd | Injectable preparations of diclofenic and its pharmaceutically acceptable salts |
CN101410012A (zh) * | 2006-03-28 | 2009-04-15 | 杰佛林制药公司 | 低剂量的非甾体抗炎药和β-环糊精的制剂 |
WO2007112272A2 (en) | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
ITMI20121205A1 (it) | 2012-07-11 | 2014-01-12 | Glycores 2000 Srl | Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione |
US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
CN103432132B (zh) * | 2013-08-31 | 2015-01-21 | 西南大学 | 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法 |
US10525137B2 (en) | 2015-12-30 | 2020-01-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
CN107126418B (zh) * | 2016-02-25 | 2020-05-29 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
EP3216443A1 (en) | 2016-03-10 | 2017-09-13 | Athenion AG | Beverage preparation capsule for delivery of a solubilisate |
IT201600075246A1 (it) | 2016-07-19 | 2018-01-19 | Jointherapeutics S R L | Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi. |
US11110073B2 (en) | 2017-03-24 | 2021-09-07 | Cadila Healthcare Limited | Storage stable aqueous injectable solution comprising diclofenac |
EP3388054A1 (en) | 2017-04-12 | 2018-10-17 | Athenion AG | Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement |
US20220280463A1 (en) | 2019-09-09 | 2022-09-08 | Ftf Pharma Private Limited | Pharmaceutical formulations comprising diclofenac |
US11707443B2 (en) | 2019-09-26 | 2023-07-25 | Rk Pharma Inc. | Storage stable aqueous parenteral solutions comprising diclofenac |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
US5554650A (en) | 1994-07-28 | 1996-09-10 | Southern Research Institute | Antiphlogistic, analgesic, antipyretic injection preparation |
SI0969856T1 (en) * | 1997-03-12 | 2005-06-30 | Abbott Laboratories | Hydrophilic binary systems for the administration of cyclosporine |
US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US20020016359A1 (en) * | 2000-06-29 | 2002-02-07 | Hellberg Mark R. | Compositions and methods of treating neurodegenerative diseases |
WO2003002153A1 (en) * | 2001-06-28 | 2003-01-09 | Wyeth | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
-
2004
- 2004-06-22 IT IT001245A patent/ITMI20041245A1/it unknown
-
2005
- 2005-06-15 JP JP2005174529A patent/JP5113323B2/ja active Active
- 2005-06-17 CN CNB2005100768303A patent/CN100569230C/zh active Active
- 2005-06-20 KR KR1020050053096A patent/KR101202649B1/ko active IP Right Grant
- 2005-06-21 US US11/158,517 patent/US7423028B2/en active Active
- 2005-06-21 PL PL05105474T patent/PL1609481T3/pl unknown
- 2005-06-21 DK DK05105474T patent/DK1609481T3/da active
- 2005-06-21 CA CA2510813A patent/CA2510813C/en active Active
- 2005-06-21 EP EP05105474A patent/EP1609481B1/en active Active
- 2005-06-21 PT PT05105474T patent/PT1609481E/pt unknown
- 2005-06-21 AT AT05105474T patent/ATE373489T1/de active
- 2005-06-21 ES ES05105474T patent/ES2293482T3/es active Active
- 2005-06-21 DE DE602005002495T patent/DE602005002495T2/de active Active
Non-Patent Citations (2)
Title |
---|
药剂辅料大全. 罗明生,高天惠,504-507,四川科学技术出版社. 1993 |
药剂辅料大全. 罗明生,高天惠,504-507,四川科学技术出版社. 1993 * |
Also Published As
Publication number | Publication date |
---|---|
PL1609481T3 (pl) | 2008-02-29 |
KR20060049413A (ko) | 2006-05-18 |
DK1609481T3 (da) | 2008-01-07 |
DE602005002495T2 (de) | 2008-06-12 |
US7423028B2 (en) | 2008-09-09 |
DE602005002495D1 (de) | 2007-10-31 |
CN1711996A (zh) | 2005-12-28 |
CA2510813C (en) | 2013-02-12 |
EP1609481A1 (en) | 2005-12-28 |
PT1609481E (pt) | 2007-12-31 |
ATE373489T1 (de) | 2007-10-15 |
US20050282776A1 (en) | 2005-12-22 |
ITMI20041245A1 (it) | 2004-09-22 |
EP1609481B1 (en) | 2007-09-19 |
KR101202649B1 (ko) | 2012-11-19 |
JP5113323B2 (ja) | 2013-01-09 |
ES2293482T3 (es) | 2008-03-16 |
CA2510813A1 (en) | 2005-12-22 |
JP2006008684A (ja) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100569230C (zh) | 含有双氯芬酸钠和β-环糊精的可注射药物组合物 | |
US11944629B2 (en) | Concentrated methotrexate solutions | |
JP2006522133A (ja) | 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション | |
JP2005538068A (ja) | 高濃度のヒト成長ホルモン(hGH)とフェノールを含有する液剤 | |
CN105431145B (zh) | 用于呋塞米的皮下施用的药物制剂 | |
US5124152A (en) | Parenteral formulation of metolazone | |
JP5070670B2 (ja) | N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤およびその製造方法 | |
US11672863B2 (en) | Enhanced solubility drug-containing formulations | |
US4289783A (en) | Etomidate-containing compositions | |
AU2004263036B2 (en) | Glycyrrhizin high-concentration preparation | |
CA2496121A1 (en) | Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy | |
US10772895B2 (en) | Pharmaceutical composition | |
CN112472667B (zh) | 一种维他昔布长效注射液及其制备方法和应用 | |
TWI246927B (en) | One kind of concentrated emulsion containing Paclitaxel (taxane) | |
MXPA01001490A (es) | Acido acetilsalicilico entregado transdermalmente. | |
JP2003321353A (ja) | ビタミン含有製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060217 Address after: Lugano Switzerland 6903 Applicant after: Altgon AG Address before: Swiss Manzano 13-CH-6903 Applicant before: IBSA Inst Biochimique SA |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |